Tag: Extends

Quoin Pharmaceuticals, Inc. ASHBURN, Va., March 01, 2022 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that its wholly-owned subsidiary, Quoin Pharmaceuticals, Inc., has extended its exclusive Distribution Agreement with ER-Kim, a partner for biotech companies in Central and […]